The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...
The mother and daughter received identical diagnoses just over a year apart of multiple myeloma, a blood cancer that occurs ...
Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...
The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...
Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer ...
Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
An immunotherapy kept multiple myeloma at bay for over 80 percent of patients in a three-year clinical trial, and the FDA ...
Study Finds on MSN
Men face double the odds of advanced multiple myeloma at diagnosis
In A Nutshell Men have double the odds of presenting with stage III multiple myeloma compared to women, even after accounting ...
A new "double-pronged" CAR T immunotherapy recognizes two distinct features of multiple myeloma to destroy the cancer more ...
Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for relapsed patients. This year brought major advances across the multiple ...
Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback